Prontogest 400 mg 30 pessary

Tradename

Prontogest

Prontogest

Composition

Each pessary contains:

Progesterone 400 mg

Auxiliary components:

Solid fat, stearolpolyxylglucerides, sorbitol acid, cocoa butter, purified water.

Properties

The active ingredient of Prontogest@ is progesterone, which is identical to the natural hormone of the corpus luteum of the ovary. By binding to receptors on the surface of cells of target organs, it penetrates into the nucleus, where it activates DNA and stimulates RNA synthesis. Promotes the transition of the uterine mucosa from the proliferation phas caused by the follicular hormone estradiol into the secretory phase. After fertilization, it promotes the transition to a state necessary for the development of a fertilized egg.

Reduces the excitability and contractility of the muscles of the uterus and fallopian tubes. Promotes the formation of a normal endometrium. Stimulates the development of the terminal elements of the mammary gland, induces lactation. By stimulating protein lipase, it increases fat stores, increases glucose utilization. By increasing the concentration of basal and stimulated insulin, promotes the accumulation of glycogen in the liver, increases the production of pituitary gonadotropic hormones; reduces azotemia, increases the excretion of nitrogen in the urine.

Indications

@ MHT in case of progesterone deficiency with non-functioning (absent) ovaries (egg donation);

@ prevention (prophylaxis) of premature birth in women at risk (with shortening of the cervix and / or the presence of anamnestic data of premature birth and / or premature rupture of membranes); support of the luteal phase during

preparation for in vitro fertilization; support of the luteal phase in a spontaneous or induced menstrual cycle; premature menopause;

Contraindications

deep vein thrombosis, thrombophlebitis; thromboembolic disorders (pulmonary embolism, myocardial infarction, stroke), intracranial hemorrhage, or a history of

these conditions / diseases; vaginal bleeding of unknown origin;

incomplete abortion;

Side effects

It was reported about individual cases of the development of reactions of local intolerance to the components of the drug (in particular, soy lecithin) in the form of hyperemia of the vaginal mucosa, burning, itching, oily discharge. Systemic side effects with intravaginal use of the drug in recommended doses, in particular, drowsiness or dizziness (observed with oral administration of the drug), were not observed.

Storage method:

At a temperature not higher than 30 degrees.